How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world

Pretta, Andrea

Primo

Writing – Original Draft Preparation

;Spanu, Dario

Secondo

Supervision

;Mariani, Stefano

Supervision

;Liscia, Nicole;Ziranu, Pina;Pusceddu, Valeria;Puzzoni, Marco;Massa, Elena

Supervision

;Scartozzi, Mario

Penultimo

Project Administration

;Lai, Eleonora

Ultimo

Writing – Review & Editing

2022-01-01

---

Abstract

As underlined in the minireview by Blomstrand et al, given the poor prognosis and the paucity of data on a therapeutic sequence in pancreatic ductal adenocarcinoma (PDAC), additional randomized controlled trials and real-world evidence studies addressing current and novel regimens are needed. The real-world outcomes of first-line chemotherapy regimens such as FOLFIRINOX and gemcitabine/nab-paclitaxel are thoroughly reviewed and seem to be largely generalizable in a real-world context. Regarding second-line chemotherapy, the key question about the optimal sequence of regimens remains uncertain. Precisely in this setting, it is therefore useful to encourage the implementation of clinical studies that may contribute to the scarcity of data available up to now. We report our experience with a small group of patients treated with second-line liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin. To improve the treatment of patients affected by PDAC, it is useful to identify subgroups of patients who may benefit from target treatments (e.g., BRCA mutant) and it is also important to focus on any prognostic factors that may affect the survival and treatment of these patients.